PNC-27 Induces Necrosis in Leukemia Cells by Targeting Membrane HDM-2, Sparing Normal Hematopoietic Cells

Effective treatments for acute myelogenous leukemia (AML) often come with significant side effects due to their lack of specificity for cancer cells. A promising strategy involves targeting proteins uniquely expressed or overexpressed on cancer cell membranes. The HDM-2 protein, a key regulator of p53 degradation, is often overexpressed in various cancers, including leukemia, and its membrane-bound form presents a distinct therapeutic target. PNC-27, an anticancer peptide, is designed to specifically bind to membrane HDM-2, forming cytotoxic pores that lead to cancer cell death while potentially sparing healthy cells.

Researchers investigated the membrane expression of HDM-2 and the effects of PNC-27 on three human non-stem cell acute myelogenous leukemia cell lines: U937 (acute monocytic leukemia), OCI-AML3 (acute myelomonocytic leukemia), and HL60 (acute promyelocytic leukemia). Cell surface membrane HDM-2 expression was quantified using flow cytometry. Cell viability was assessed via MTT assay, while direct cytotoxicity was measured by lactate dehydrogenase (LDH) release. The induction of apoptotic markers, annexin V and caspase-3, was also evaluated to distinguish between necrotic and apoptotic cell death pathways.

All three investigated leukemia cell lines—U937, OCI-AML3, and HL-60—demonstrated high levels of HDM-2 expression on their cell membranes. This finding supports HDM-2 as a viable target for therapeutic intervention in these leukemia subtypes. Upon treatment, PNC-27 was observed to effectively bind to the membrane-bound HDM-2 in these cells. This binding rapidly initiated a cytotoxic response. > PNC-27 treatment induced significant cell necrosis and LDH release in the leukemia cell lines within 4 h of exposure, indicating rapid and direct cell killing. The mechanism of cell death was primarily necrotic, as suggested by the LDH release data, rather than apoptotic, which would typically involve annexin V and caspase-3 activation.